Know Labs unveils wearable, non-invasive CGM set to go to FDA
WEBFeb 27, 2024 · A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs] Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system. Seattle-based Know Labs first announced its initial prototype last June.It says KnowU is the result of an accelerated development process over the past eight months.
Tandem Diabetes Care launches Mobi automated insulin pump
WEBFeb 13, 2024 · The Mobi miniature, durable automated insulin patch pump worn on a hiker’s leg. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq:TNDM) announced today that it kicked off the U.S. commercial launch of its Mobi insulin patch pump. The San Diego-based company says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable automated insulin ...
The company behind Narcan looks toward a treatment for fentanyl ...
WEBMar 13, 2018 · A nasal spray designed to reverse opioid overdoses called Narcan has become a life-saving tool used by police departments and communities around the country. Now, the company that created Narcan – Opiant Pharmaceuticals (NSDQ: OPNT) – is hoping that its latest drug-device combination can …
How Medtronic developed its latest automated insulin delivery tech
WEBJune 25, 2024 By Sean Whooley. The MiniMed 780G with the Guardian 4 sensor. [Image courtesy of Medtronic] In 2011, Lou Lintereur says Medtronic began “getting more serious” about commercializing automated insulin delivery technology. This process started out simply and built up to the closed-loop technologies we know today, like the MiniMed ...
Medtronic must face pain-pump lawsuit - Drug Delivery Business
WEBMarch 15, 2021 By Nancy Crotti. Medtronic’s SynchroMed II infusion pump (Image courtesy of Medtronic) A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic ...
How Embecta started strong as a standalone company - Drug …
WEBEmbecta starts 2023 off right. The company kicked off its first full calendar year as a standalone company by opening up its new headquarters. The 55,600-square-foot office suite offers employees both tools and flexibility to collaborate. It includes ample open workspace, spaces for video conferencing, huddle rooms and reservable private spaces.
Baxter has a serious recall involving infusion pump software
WEBAug 12, 2021 · The FDA issued a Class I recall — the most serious kind of recall — for Baxter’s Dose IQ safety software program. Baxter designed its Dose IQ safety software as a standalone computer-based software program that allows care providers to create a drug library of pre-programmed dosing information for specific medications, which are delivered into a person’s body in controlled amounts ...
Update: Isis Biopolymer raises another $3 million
WEBMar 3, 2010 · Isis Biopolymer Inc., a company developing a new generation of non-invasive drug delivery patches, has raised $3 million through an equity sale to existing investors. The Providence, R.I.-based firm has developed the Isis Patch, a compact, wireless, active iontophoretic patch using a design that implements advances in microprocessors, thin film ...
FDA clears updated BD Alaris infusion system - Drug Delivery …
WEBJul 21, 2023 · The Alaris infusion system. [Image courtesy of BD] BD (NYSE:BDX) announced today that the FDA granted 510(k) clearance for its updated Alaris infusion system. Shares of BDX closed out Friday evening priced at $264.84 each. They ticked up significantly after market close on the back of the Alaris news, rising 5.9% to …
Report: Insulet trumps Medtrum again in French patent spat
WEBFeb 28, 2024 · Left: a diagram of the Insulet insulin pump patent in question. Top right: The Insulet Omnipod 5. Bottom right: The Medtrum TouchCare Nano. JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet (Nasdaq:PODD) in its patent battle with Medtrum.. According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390).